SCHEMBL26679803

SCHEMBL26679803

COCCNc1cc2ccc(Br)cc2cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.46
HCAR3 P49019 1/20 0.45
CLK4 Q9HAZ1 3/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2C19 P33261 3/20 0.41
USP2 O75604 1/20 0.41
APEX1 P27695 1/20 0.41
CASP7 P55210 1/20 0.41
GSK3A P49840 1/20 0.41
CDK9 P50750 1/20 0.41
CDK5 Q00535 1/20 0.41
TAOK1 Q7L7X3 1/20 0.41
KDM4E B2RXH2 3/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
HSD17B10 Q99714 3/20 0.39
ALOX15 P16050 2/20 0.39
HIF1A Q16665 1/20 0.39
TRIM33 Q9UPN9 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182806 0.79 HCAR3 (0.59) HCAR3ALDH1A1KDM4EHIF1ATSHR
SCHEMBL26686762 0.77 LRRK2 (0.50) HCAR3CLK4ALDH1A1CYP1A2CYP2C19
SCHEMBL5495483 0.76 BRAF (0.43) ALDH1A1
SCHEMBL26679763 0.76 HCAR3 (0.41) ABL1HCAR3CLK4ALDH1A1CYP1A2
SCHEMBL30637866 0.76 ABL1 (0.47) ABL1HCAR3CLK4CDK5MAP4K4
SCHEMBL2671319 0.75 ABL1 (0.55) ABL1CLK4ALDH1A1CYP1A2CYP2C19
SCHEMBL17469874 0.72 EGFR (0.53) CLK4ALDH1A1GSK3ACDK9CDK5
SCHEMBL26679766 0.70 HCAR3 (0.44) HCAR3CLK4ALDH1A1CYP1A2CYP2C19
SCHEMBL24284200 0.70 HCAR3 (0.49) HCAR3CLK4ALDH1A1CYP1A2CYP2C19
SCHEMBL25706056 0.69 CYP1A2 (0.54) HCAR3CLK4ALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340530-A1 GCN2 INHIBITOR (as amended) IP2IPO INNOVATIONS LTD (GB) 2025-11-06 US disclosed
EP-4522610-A1 GCN2 INHIBITORR IP2IPO Innovations Limited (GB) 2025-03-19 EP disclosed
CN-119451955-A GCN2 inhibitors IP2IPO创新有限公司 2025-02-14 CN disclosed
WO-2023218195-A1 GCN2 INHIBITORR IP2IPO INNOVATIONS LIMITED (GB) 2023-11-16 WO disclosed
WO-2023218195-A1 GCN2 INHIBITORR IP2IPO INNOVATIONS LIMITED (GB) 2023-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340530-A1 GCN2 INHIBITOR (as amended) EIF2AK4, GCN1, GCGR ABL1 2057/4885HCAR3 3867/4885CLK4 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.